Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
| ▸ | TPO | P07202 | 1/20 | 0.36 |
| ▸ | EPX | P11678 | 1/20 | 0.36 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955846 | 1.00 | MGMT (0.42) | MGMTADORA2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL2555167 | 0.84 | MGMT (0.51) | MGMTADORA2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL2555484 | 0.84 | MGMT (0.51) | MGMTADORA2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14659541 | 0.80 | MGMT (0.48) | MGMTADORA2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14963617 | 0.80 | MGMT (0.51) | MGMTADORA2AHPGDCYP3A4CYP1A2 | |
| SCHEMBL8898448 | 0.80 | MGMT (0.51) | MGMTADORA2AHPGDCYP3A4CYP1A2 | |
| SCHEMBL14955424 | 0.80 | NSD3 (0.52) | ADORA2AHPGDCYP3A4ADORA1ALDH1A1 | |
| SCHEMBL2567895 | 0.80 | NSD3 (0.52) | ADORA2AHPGDCYP3A4ADORA1ALDH1A1 | |
| SCHEMBL2575266 | 0.80 | HPRT1 (0.57) | CYP3A4TYMPALDH1A1MEN1KMT2A | |
| SCHEMBL2575270 | 0.80 | HPRT1 (0.57) | CYP3A4TYMPALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | MGMT 2300/4885ADORA2A 660/4885HPGD 4585/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | MGMT 815/4885ADORA2A 169/4885HPGD 4151/4885 |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | NSUN2, BCDIN3D, RNGTT | MGMT 2493/4885ADORA2A 632/4885HPGD 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.